** Shares of transdermal pharma products maker Nutriband NTRB.O rise ~28% to $6.67
** Brokerage Noble Capital starts coverage on NTRB with "outperform" rating and sets PT at $13
** PT represents a 148% upside to the stock's last
** NTRB is developing Aversa, a proprietary technology that makes transdermal patches safer by preventing abuse and misuse of potent opioids like fentanyl
** Brokerage says NTRB's tech has "abuse-deterrent" features that differentiate it from other transdermal patches on the market
** Also notes NTRB's partnership to add the Aversa technology to Kindeva's transdermal fentanyl patch could be a highly effective means to stop misuse
** NTRB shares doubled in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))